Primary Objectives:~To determine the maximum tolerated dose (MTD) of sodium selenite when given in combination with palliative radiation therapy~To assess the safety and tolerability of the combination of sodium selenite and palliative radiation therapy in metastatic cancer~Secondary Objectives:~To assess the pharmacokinetics of sodium selenite~To evaluate the anti tumor activity of sodium selenite and palliative radiation therapy when given in combination~OUTLINE:~Patients receive sodium selenite orally (PO) 2 hours before daily radiation therapy treatments. Treatment continues for the duration of the course of radiation therapy in the absence of disease progression or unacceptable toxicity.~After completion of study treatment, patients are followed up every 2 months.
The purpose of this study is to determine the maximum-tolerated dose (MTD) of sodium selenite when administered in combination with radiation therapy to subjects with metastatic cancer based on safety and tolerability.